Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 1 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Alume Biosciences Inc. has 2 pending office actions in Biotechnology & Pharmaceuticals. Both matters are associated with 1 distinct examiner and 1 distinct art unit, placing the current docket within one examination channel.
SCHLIENTZ, LEAH H is the busiest examiner, with 2 pending matters. The shared assignment makes it practical to review the matters together for recurring positions, disclosure support, and claim language, while preserving separate analyses of each action. Counsel can also use the common art-unit context to maintain a consistent prosecution record.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SCHLIENTZ, LEAH H | 2 | 41.8% | +38.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18254565 | NERVE TARGETING PEPTIDES AND METHODS OF USE | SCHLIENTZ, LEAH H | 70d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18254565 | NERVE TARGETING PEPTIDES AND METHODS OF USE | SCHLIENTZ, LEAH H | 70d |
| 18780117 | METHODS AND COMPOSITIONS FOR VISUALIZING A URETER IN A SURGICAL PROCEDURE | SCHLIENTZ, LEAH H | — |
| Art Unit | Apps |
|---|---|
| 1618 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18780117 | METHODS AND COMPOSITIONS FOR VISUALIZING A URETER IN A SURGICAL PROCEDURE | SCHLIENTZ, LEAH H | 1618 | §103Other | Non-Final OA | — | Pending | Jul 22, 2024 |
| 18254565 | NERVE TARGETING PEPTIDES AND METHODS OF USE | SCHLIENTZ, LEAH H | 1618 | §102§103 | Final Rejection | 70d | Pending | May 25, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAlume Biosciences Inc. has 2 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Leah H Schlientz has the most, with 2 of Alume Biosciences Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
